Phase 1 N=245 A Study of Two Formulations of Ixekizumab in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ixekizumab — 9.66; 9.97 micrograms per milliliter (ug/mL)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=18 This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)
SARS-CoV-2 Infection
Primary: Number of Patients With TEAEs — 3; 4; 3; 1 Participants
Phase 1 N=25 Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes
Narcolepsy With Cataplexy
Primary: The Insulin-like Growth Factor 1 (IGF-1) Measured in Fasting Conditions at Baseline (Visit 2) — 207.4 ng/mL
Phase 1 N=12 To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.
Asthma
Primary: AUC0-t — 435; 1164 h*pg/mL
Phase 1 N=48 S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia
Acute Leukemias of Ambiguous Lineage · B-cell Adult Acute Lymphoblastic Leukemia · Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia
Primary: MTD of Inotuzumab Ozogamicin With CVP for Patients With Relapsed or Refractory CD22+ Acute Leukemia — 0.8; 0.5; 0.5 mg/m^2
Phase 1 N=32 COVID-19 Convalescent Plasma for Mechanically Ventilated Population
Covid-19
Primary: Participants With Serious Adverse Events. — 22 Participants
Phase 1 N=16 Reoxygenation After Cardiac Arrest II (REOX II Study)
Cardiac Arrest
Primary: Plasma Isofurans (pg/mL)/Isoprostanes (pg/mL) Ratio
Phase 1 N=170 Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution
Blood Donors
Primary: Red Blood Cell Post-filtration Recovery — 92.57; 92.70; 90.96; 90.23 % recovery at day 0
Phase 1 N=29 Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies
Relapsed/Refractory B-cell Malignancies
Primary: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs) — 100.0; 100.0; 100.0; 100.0 percentage of participants
Phase 1 N=124 Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness — 12; 11; 15; 8 Participants
Phase 1 N=48 A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
Acute Myeloid Leukemia
Primary: Number of Participants With Dose-limiting Toxicities (DLTs): Monotherapy Cohort — 0; 0; 0 Participants
Phase 1 N=36 Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli
Urinary Tract Infections
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by DAIDS v2.1 — 0; 0 Participants
Phase 1 N=37 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 3; 7; 9; 9 Participants
Phase 1 N=9 A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors
Neoplasms · Breast Neoplasms
Primary: Dose Escalation: Number of Participants With Dose-Limiting Toxicities (DLT) — 0; 0 Participants
Phase 1 N=69 Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)
Myelofibrosis
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants